查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
終末期腎病治療方法（移植、透析）、地區（亞太、北美、MEA、歐洲、拉丁美洲）的市場規模、份額、趨勢分析報告2022-2030
市場調查報告書
商品編碼
1097153

終末期腎病治療方法（移植、透析）、地區（亞太、北美、MEA、歐洲、拉丁美洲）的市場規模、份額、趨勢分析報告2022-2030

End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Region (APAC, North America, MEA, Europe, Latin America), And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 171 Pages | 商品交期: 2-10個工作天內

價格

終末期腎病的市場增長和趨勢

據正觀研究最新報告顯示，全球終末期腎病市場在預測期內將達到12.9%的複合年增長率，到2030年預計將達到2616.4億美元。

腎功能衰竭患者人數的增加、醫院和急診醫療中心的快速增加以及住院率的提高被認為是推動市場增長的因素。慢性腎髒病 (CKD) 是導致患者腎功能衰竭率增加的主要原因之一。據美國疾病控制與預防中心估計，美國有超過 3700 萬人患有 CKD，全世界有超過 5 億人（佔世界人口的 12-18%）受到影響。因此，對透析和腎移植的需求正在增加。 COVID-19 流行病影響了醫療保健行業，ESRD 患者感染病毒的風險增加，因為他們需要經常去醫院進行透析。在大多數國家，以中心為基礎的血液透析是主要的腎臟替代療法，是近 90% 的 ESRD 患者的選擇。血液透析患者必須在醫院至少逗留4小時，每週3次，並且會經常與醫務人員和其他患者接觸。這些因素會增加感染的風險。治療腎衰竭的技術進步也是加速 ESRD 市場增長的因素。例如，可穿戴人工腎 (WAK) 技術的創新可以控制血壓，改善血液中廢物的清除，此外還可以減輕 ESRD 或 CKD 患者飲食不嚴格時對心臟的壓力。該設備旨在讓患者過上健康的生活，從而減少體重增加。因此，WAK 的技術進步有可能降低透析患者的死亡率並提高患者的生活質量。 WAK 原型由一家創新公司設計並獲得專利，於 2016 年獲得美國 FDA 批准用於人體臨床試驗。

終末期腎功能衰竭市場報告亮點

  • 2021年終末期腎病全球市場中，透析療法以其易用性和應急便利性成為主流。
  • 該板塊進一步細分為腹膜透析、血液透析、可穿戴人工腎。
  • 2021 年，亞太地區的銷售額份額將最高，預計 2022 年至 2030 年的複合年增長率將進一步增長。
  • 這種增長是由於 CKD/ESRD 患者人數眾多以及該大陸高血壓和糖尿病的高發病率。

目錄

第 1 章調查方法及範圍

  • 市場細分和範圍
    • 處理
    • 區域範圍
    • 估計/預測時間線
  • 調查方法
  • 資訊採購
    • 購買的數據庫:
    • GVR 內部數據庫
    • 二次材料
    • 初步調查
    • 初步調查詳情
  • 資訊或數據分析
    • 數據分析模型
  • 市場製定與驗證
  • 型號詳情
    • 產品流分析（模型一）
      • 方法一:產品流方法
    • 量價分析（模型二）
      • 方法二:量價分析
  • 二次材料清單
  • 主要來源列表
  • 縮寫列表
  • 目的
    • 目的 1
    • 目的 2
    • 目的 3
    • 目的 4

第 2 章執行摘要

  • 市場展望
  • 細分市場展望
  • 競爭考慮

第 3 章終末期腎功能衰竭市場的變量、趨勢和範圍

  • 市場體系展望
    • 母公司市場展望
    • 輔助市場展望
  • 滲透率和增長前景映射
  • 產品管線分析
  • 用戶視角分析
    • 消費者行為分析
    • 市場影響者分析
  • 關鍵最終用戶列表
  • 監管框架
  • 市場動態
    • 市場促進因素分析
      • 糖尿病和高血壓患病率增加
      • 技術先進的產品介紹
      • 越來越多的慢性腎病患者
    • 市場抑制因素分析
      • 並發症風險
      • 透析產品的嚴格監管政策
  • 終末期腎病:市場分析工具
    • 行業分析-Porter's
    • 害蟲的 SWOT 分析

第 4 章終末期腎功能衰竭市場:細分分析，按治療，2018-2030

  • 定義和範圍
  • 2021 年和 2030 年治療市場份額分析
  • 細分儀表板
  • 2018-2030 年全球終末期腎病市場（按治療）
  • 2018-2030 年市場規模及預測及趨勢分析
    • 透析
      • 2018-2030年透析市場
    • 移植
      • 2018-2030年移植市場

第 5 章終末期腎功能衰竭市場:區域市場分析，按治療，2018-2030

  • 定義和範圍
  • 2021 年和 2030 年區域市場份額分析
  • 區域市場儀表板
  • 區域市場概況
  • 按因素（政治和法律、經濟和技術）的 SWOT 分析
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 2016-2030 年市場規模和預測、數量和趨勢分析
  • 北美
    • 2018-2030 年北美終末期腎功能衰竭市場
    • 美國
      • 2018-2030 年美國終末期腎功能衰竭市場
    • 加拿大
      • 2018-2030 年加拿大終末腎功能衰竭市場
  • 歐洲
    • 2018-2030 年歐洲終末期腎功能衰竭市場
    • 英國
      • 2018-2030 年英國終末期腎功能衰竭市場
    • 德國
      • 2018-2030年德國終末期腎病市場
    • 法國
      • 2018-2030年法國終末期腎病市場
    • 意大利
      • 2018-2030 年意大利終末期腎病市場
    • 西班牙
      • 2018-2030 年西班牙終末期腎功能衰竭市場
  • 亞太地區
    • 2018-2030 年亞太地區終末期腎功能衰竭市場
    • 日本
      • 2018-2030年日本終末期腎病市場
    • 中國（大陸）
      • 2018-2030年中國（大陸）終末期腎功能衰竭市場
    • 印度
      • 2018-2030 年印度終末期腎功能衰竭市場
    • 澳大利亞
      • 2018-2030 年澳大利亞終末腎功能衰竭市場
    • 韓國
      • 2018-2030 年韓國終末期腎病市場
  • 拉丁美洲
    • 2018-2030 年拉丁美洲終末期腎功能衰竭市場
    • 巴西
      • 2018-2030 年巴西終末期腎功能衰竭市場
    • 墨西哥
      • 2018-2030 年墨西哥終末期腎功能衰竭市場
    • 阿根廷
      • 2018-2030 年阿根廷終末腎衰竭市場
    • 哥倫比亞
      • 2018-2030 年哥倫比亞終末期腎病市場
  • 多邊環境協定
    • 2018-2030 年 MEA 終末期腎功能衰竭市場
    • 南非
      • 2018-2030 年南非終末期腎功能衰竭市場
    • 沙特阿拉伯
      • 2018-2030 年沙特阿拉伯終末期腎功能衰竭市場
    • 阿拉伯聯合酋長國
      • 2018-2030 年阿拉伯聯合酋長國終末期腎功能衰竭市場

第 6 章終末期腎功能衰竭市場-競爭分析

  • 主要市場參與者的近期趨勢和影響分析
    • Nipro Corporation
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商情況
    • 主要客戶
    • 2021 年主要公司的市場份額分析
    • 重大交易和戰略聯盟
      • 推出新產品
      • 擴展
      • 獲取
      • 營銷與推廣
    • 市場進入策略
  • 上市公司
    • 公司市場分析
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 私人公司
    • 主要初創企業列表
    • 區域網絡圖
    • 公司市場分析
  • 公司簡介
    • Medtronic
      • 公司簡介
      • 財務表現
      • 產品基準
      • 戰略舉措
    • Fresenius Medical Care AG & Co. KGaA
      • 公司簡介
      • 財務表現
      • 產品/服務基準
      • 戰略舉措
    • B. Brown Melsungen AG
      • 公司簡介
      • 財務表現
      • 產品/服務基準
    • Baxter International, Inc.
      • 公司簡介
      • 財務表現
      • 產品基準
      • 戰略舉措
    • Asahi Kasei Medical Co., Ltd.
      • 公司簡介
      • 財務表現
      • 產品基準
      • 戰略舉措
    • Cantel Medical
      • 公司簡介
      • 財務表現
      • 產品基準
      • 戰略舉措
    • BD
      • 公司簡介
      • 財務表現
      • 產品基準
      • 戰略舉措
    • Nikkiso Co., Ltd.
      • 公司簡介
      • 財務表現
      • 產品基準
      • 戰略舉措
    • JMS Co. Ltd.
      • 公司簡介
      • 財務表現
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68038-434-5

End Stage Renal Disease Market Growth & Trends:

The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period, according to a new report by Grand View Research, Inc. Increasing number of patients suffering from kidney failure, rapid increase in the volume of hospitals & urgent care centers, and growing hospital admission rates are among the few factors propelling the market growth. Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients. According to the CDC, it is estimated that more than 37 million people in the U.S. suffer from CKD, whereas globally more than 500 million people (12-18% of the world population) are affected. As a result, increasing the demand for dialysis or kidney transplant. The COVID-19 pandemic has impacted the healthcare industry and people suffering from ESRD are at a higher risk of contracting this virus, as they have to visit the hospitals often for dialysis. Center-based hemodialysis is the main renal replacement medium in most countries, with almost 90% of the ESRD population opting for it. Hemodialysis patients have to stay in hospitals for 4 hours minimum, 3 times a week, and come in frequent contact with the medical staff and other patients. All these factors increase their risk of infection. Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD. For instance, the innovation of Wearable Artificial Kidney (WAK) technologies, a portable dialysis device designed to enable patients to live a healthier life as it controls blood pressure, improves clearance of wastes from the blood, and allows ESRD or CKD patients to a less strict diet, and results in lower fluid weight gain in addition to lowered stress on the heart. Thus, technical advancements in WAK have the potential to reduce mortality in dialysis patients, which thereby improves an ESRD patient's quality of life. The WAK prototypes designed and patented by innovative firms have been approved for human clinical trials by the U.S. FDA in 2016.

End Stage Renal Disease Market Report Highlights:

  • The dialysis segment dominated the global ESRD market in 2021 owing to its ease of use and emergency convenience
  • this segment is further sub-segmented into peritoneal, hemodialysis, and wearable artificial kidney
  • The Asia Pacific region dominated the market with the highest revenue share in 2021 and will expand further at the fastest CAGR from 2022 to 2030
  • This growth can be attributed to the large population of patients with CKD/ESRD, and the greater incidence of hypertension and diabetes in the continent

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Treatment
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.2 Volume Price Analysis (Model 2)
      • 1.6.2.1 Approach 2: Volume price analysis
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2. Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3. End Stage Renal Disease Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis
  • 3.4 User Perspective Analysis
    • 3.4.1 Consumer Behavior Analysis
    • 3.4.2 Market Influencer Analysis
  • 3.5 List Of Key End Users
  • 3.6 Regulatory Framework
  • 3.7 Market Dynamics
    • 3.7.1 Market Driver Analysis
      • 3.7.1.1 Growing Prevalence Of Diabetes And Hypertension
      • 3.7.1.2 Introduction Of Technologically Advanced Products
      • 3.7.1.3 Increasing Number Of Patients Suffering From Chronic Kidney Disease
    • 3.7.2 Market Restraints Analysis
      • 3.7.2.1 Risk Of Complications
      • 3.7.2.2 Stringent Regulatory Policies For Dialysis Products
  • 3.8 End Stage Renal Disease: Market Analysis Tools
    • 3.8.1 Industry Analysis - Porter's
    • 3.8.2 Swot Analysis, By Pest

Chapter 4. End Stage Renal Disease Market: Segment Analysis, By Treatment, 2018 - 2030 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Treatment Market Share Analysis, 2021 & 2030
  • 4.3 Segment Dashboard
  • 4.4 Global End Stage Renal Disease Market, by Treatment, 2018 to 2030
  • 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.5.1 DIALYSIS
      • 4.5.1.1 Dialysis market, 2018 - 2030 (USD Million)
    • 4.5.2 TRANSPLANT
      • 4.5.2.1 Transplant market, 2018 - 2030 (USD Million)

Chapter 5. End Stage Renal Disease Market: Regional Market Analysis, By Treatment, 2018 - 2030 (USD Million)

  • 5.1 Definition & Scope
  • 5.2 Regional Market Share Analysis, 2021 & 2030
  • 5.3 Regional Market Dashboard
  • 5.4 Regional Market Snapshot
  • 5.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
    • 5.5.1 North America
    • 5.5.2 Europe
    • 5.5.3 Asia Pacific
    • 5.5.4 Latin America
    • 5.5.5 Middle East and Africa
  • 5.6 Market Size, & Forecasts, Volume and Trend Analysis, 2016 to 2030
  • 5.7 North America
    • 5.7.1 North America End Stage Renal Disease Market, 2018 - 2030 (USD Million)
    • 5.7.2 U.S.
      • 5.7.2.1 U.S. end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.7.3 Canada
      • 5.7.3.1 Canada end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.8 Europe
    • 5.8.1 Europe End Stage Renal Disease Market, 2018 - 2030 (USD Million)
    • 5.8.2 U.K.
      • 5.8.2.1 U.K. end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.3 Germany
      • 5.8.3.1 Germany end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.4 France
      • 5.8.4.1 France end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.5 Italy
      • 5.8.5.1 Italy end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.6 Spain
      • 5.8.6.1 Spain end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.9 Asia Pacific
    • 5.9.1 Asia Pacific end stage renal disease Market, 2018 - 2030 (USD Million)
    • 5.9.2 Japan
      • 5.9.2.1 Japan end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.3 China (Mainland)
      • 5.9.3.1 China (Mainland) end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.4 India
      • 5.9.4.1 India end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.5 Australia
      • 5.9.5.1 Australia end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.6 South Korea
      • 5.9.6.1 South Korea end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.10 Latin America
    • 5.10.1 Latin America end stage renal disease Market, 2018 - 2030 (USD Million)
    • 5.10.2 Brazil
      • 5.10.2.1 Brazil end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.10.3 Mexico
      • 5.10.3.1 Mexico end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.10.4 Argentina
      • 5.10.4.1 Argentina end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.10.5 Colombia
      • 5.10.5.1 Colombia end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.11 MEA
    • 5.11.1 MEA end stage renal disease Market, 2018 - 2030 (USD Million)
    • 5.11.2 South Africa
      • 5.11.2.1 South Africa end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.11.3 Saudi Arabia
      • 5.11.3.1 Saudi Arabia end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.11.4 UAE
      • 5.11.4.1 UAE end stage renal disease market, 2018 - 2030 (USD Million)

Chapter 6. End Stage Renal Disease Market - Competitive Analysis

  • 6.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 6.1.1 Nipro Corporation
  • 6.2 Company Categorization
    • 6.2.1 Innovators
    • 6.2.2 Market Leaders
  • 6.3 Vendor Landscape
    • 6.3.1 Key Customers
    • 6.3.2 Key Company Market Share Analysis, 2021
    • 6.3.3 Major Deals And Strategic Alliances
      • 6.3.3.1 New Product Launch
      • 6.3.3.2 Expansion
      • 6.3.3.3 Acquisition
      • 6.3.3.4 Marketing & Promotions
    • 6.3.4 Market Entry Strategies
  • 6.4 Public Companies
    • 6.4.1 Company Market Position Analysis
    • 6.4.2 Competitive Dashboard Analysis
      • 6.4.2.1 Market Differentiators
  • 6.5 Private Companies
    • 6.5.1 List of Key Emerging Companies
    • 6.5.2 Regional Network Map
    • 6.5.3 Company Market Position Analysis
  • 6.6 Company Profiles
    • 6.6.1 Medtronic
      • 6.6.1.1 Company Overview
      • 6.6.1.2 Financial Performance
      • 6.6.1.3 Product Benchmarking
      • 6.6.1.4 Strategic Initiatives
    • 6.6.2 Fresenius Medical Care AG & Co. KGaA
      • 6.6.2.1 Company Overview
      • 6.6.2.2 Financial Performance
      • 6.6.2.3 Product/Service Benchmarking
      • 6.6.2.4 Strategic Initiatives
    • 6.6.3 B. Braun Melsungen AG
      • 6.6.3.1 Company Overview
      • 6.6.3.2 Financial Performance
      • 6.6.3.3 Product/Service Benchmarking
    • 6.6.4 Baxter International, Inc.
      • 6.6.4.1 Company Overview
      • 6.6.4.2 Financial Performance
      • 6.6.4.3 Product Benchmarking
      • 6.6.4.4 Strategic Initiatives
    • 6.6.5 Asahi Kasei Medical Co., Ltd.
      • 6.6.5.1 Company Overview
      • 6.6.5.2 Financial Performance
      • 6.6.5.3 Product Benchmarking
      • 6.6.5.4 Strategic Initiatives
    • 6.6.6 Cantel Medical
      • 6.6.6.1 Company Overview
      • 6.6.6.2 Financial Performance
      • 6.6.6.3 Product Benchmarking
      • 6.6.6.4 Strategic Initiatives
    • 6.6.7 BD
      • 6.6.7.1 Company Overview
      • 6.6.7.2 Financial Performance
      • 7.6.7.3 Product Benchmarking
      • 6.6.7.4 Strategic Initiatives
    • 6.6.8 Nikkiso Co., Ltd.
      • 6.6.8.1 Company Overview
      • 6.6.8.2 Financial Performance
      • 6.6.8.3 Product Benchmarking
      • 6.6.8.4 Strategic Initiatives
    • 6.6.9 JMS Co. Ltd.
      • 6.6.9.1 Company Overview
      • 6.6.9.2 Financial Performance
      • 6.6.9.3 Product Benchmarking
      • 6.6.9.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 U.S end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 Canada end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 Europe end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 8 Europe end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.K. end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Germany end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 France end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Italy end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Spain end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Russia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Asia Pacific end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 China end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 India end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 South Korea end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Australia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Japan end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Singapore end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 Latin America end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 24 Latin America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Brazil end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Mexico end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Argentina end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 28 Colombia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Middle East & Africa end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 30 Middle East & Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 South Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 South Arabia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 UAE end stage renal disease market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 End stage renal disease market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2021)
  • Fig. 10 Segment Outlook
  • Fig. 11 Strategy framework
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Consumer behavior analysis
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 18 End Stage Renal Disease market: Treatment movement analysis
  • Fig. 19 Segment dashboard
  • Fig. 20 End Stage Renal Disease market treatment outlook: Key takeaways
  • Fig. 21 Dialysis market, 2018 - 2030 (USD Million)
  • Fig. 22 Transplantation market, 2018 - 2030 (USD Million)
  • Fig. 23 End Stage Renal Disease market: End use movement analysis
  • Fig. 24 Regional outlook, 2021 & 2030
  • Fig. 25 Regional market dashboard
  • Fig. 26 Regional market place: Key takeaways
  • Fig. 27 North America, SWOT, by PEST
  • Fig. 28 Europe, SWOT, by PEST
  • Fig. 29 Asia Pacific, SWOT, by PEST
  • Fig. 30 Latin America, SWOT, by PEST
  • Fig. 31 Middle East and Africa, SWOT, by PEST
  • Fig. 32 North America end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 36 U.K. End Stage Renal Disease market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 38 France end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 42 Japan end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 43 China (Mainland) end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 44 India end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 51 Colombia end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 52 MEA end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 56 Company market share analysis, 2021
  • Fig. 57 Strategy mapping
  • Fig. 58 Market differentiators
  • Fig. 59 Regional network map